GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » Inventories, Finished Goods

WuXi XDC Cayman (HKSE:02268) Inventories, Finished Goods : HK$0 Mil (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Inventories, Finished Goods?

WuXi XDC Cayman Inventories, Finished Goods Historical Data

The historical data trend for WuXi XDC Cayman's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Inventories, Finished Goods Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
- - - -

WuXi XDC Cayman Quarterly Data
Dec20 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23
Inventories, Finished Goods Get a 7-Day Free Trial - - - - -

WuXi XDC Cayman Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

WuXi XDC Cayman (HKSE:02268) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » Inventories, Finished Goods
Comparable Companies
Traded in Other Exchanges
L74:Germany
Address
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
Website
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (HKSE:02268) Headlines

No Headlines